RxDoctor Payments Data

Prasanna Allada

Family Medicine · Huntsville, ALNPI 1902197825

Payments from drug & device makers

$16,153in general payments, 2019–2025

Across 1,123 payments — averaging $14.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$726
  • plus $7K from 31 others

What the payments were for

  • Food & beverage$16,138100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,153 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$151,739
Medicare patients
451
Services billed
3,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide180$216,369
JardianceEmpagliflozin141$161,695
EliquisApixaban125$138,402
MounjaroTirzepatide56$77,312
RybelsusSemaglutide31$68,780
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$62,026
TrulicityDulaglutide33$56,310
XareltoRivaroxaban31$37,989
MyrbetriqMirabegron33$29,716
FarxigaDapagliflozin Propanediol23$24,796
LinzessLinaclotide19$20,271
Synjardy XrEmpagliflozin/Metformin Hcl13$18,866
EntrestoSacubitril/Valsartan12$16,816
JanuviaSitagliptin Phosphate14$12,953
Tresiba Flextouch U-200Insulin Degludec14$12,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$3,285$285,149211 claims
Boehringer IngelheimJardiance, Synjardy Xr$636$180,561154 claims
PfizerEliquis, Paxlovid$1,194$142,656155 claims
Lilly USA, LLCMounjaro, Trulicity$1,750$133,62289 claims
GSKTrelegy Ellipta$726$62,02636 claims
Johnson & JohnsonXarelto$280$37,98931 claims
AstraZenecaFarxiga, Symbicort$1,185$31,77435 claims
Astellas Pharma US IncMyrbetriq$525$29,71633 claims
AbbVieLinzess, Synthroid$1,045$24,00268 claims
NovartisEntresto$57$16,81612 claims
MerckJanuvia$172$12,95314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →